



28 May 2019

**Byotrol plc**  
("Byotrol", or the  
"Company")

**Appointment of Chief Financial Officer**

**Award of Options**

Byotrol plc, the AIM quoted anti-microbial technology company, is pleased to announce the appointment of Nic Hellyer as CFO and Executive Director of the Company with immediate effect.

Nic is a Chartered Accountant (FCA) and former investment banker with over 25 years' corporate finance experience, mostly at UBS and HSBC, managing corporate development, M&A and fund raisings for growth and entrepreneurial companies (both public and private).

He is being employed on a part-time basis by the Company alongside his other business interests, which include a part-time CFO role at Pelatro plc, another AIM-listed company.

The Company has today granted Nic Hellyer options over 2,000,000 shares under the Byotrol plc approved share option scheme at a strike price of 2.6p. These options are exercisable in three tranches from 28 May 2020, 2021 and 2022 subject to the Company's share price reaching hurdles of 3.5p, 5.5p and 7.5p.

At the date of this announcement, Mr Hellyer does not have any other beneficial interest in the ordinary shares of the Company.

In addition to the above, the Company is issuing a further 1,000,000 shares to a new employee under the Byotrol plc share option scheme, on the same terms as detailed above.

**John Langlands, Chairman of the Company, said,**

"We are delighted to welcome Nic to the Board of the Byotrol. He has a wealth of experience from his time in the investment banking world, including extensive experience in the smaller company environment, and has directly relevant experience as a Finance Director for an SME on AIM. His skills will be invaluable to us as we continue to grow and develop Byotrol."

***Current directorships and/or partnerships of Nicholas James Hellyer (56):***

***Former directorships and/or partnerships (within the last five years):***

***Defenx plc***

***The Marketing Group plc***

***Pelatro Plc***

***Reeflive Limited***

***Weyland-Yutani Property Management Limited***

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.

*The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.*

**Enquiries:**

Byotrol plc  
John Langlands –  
Chairman  
David Traynor – Chief  
Executive

01925 742 000

finnCap Ltd  
Geoff Nash / Kate Bannatyne – Corporate Finance  
Richard Chambers – ECM

020 7220 0500

**Notes to Editors:**

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to [www.byotrol.co.uk](http://www.byotrol.co.uk)

**Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):**

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Nic Hellyer
<b>2.</b>	<b>Reason for the Notification</b>	
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Byotrol Plc
b)	LEI	213800AJMTSTIPA59A34
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the Financial instrument, type of instrument	options over ordinary shares of 0.25p each
	Identification code	GB00B0999995
b)	Nature of the transaction	Award of Options to subscribe for Ordinary Shares
c)	Price(s) and volume(s)	Volume - 2,000,000

		Exercise Price – 2.6 pence
d)	Aggregated information:	See 4(c) above
e)	Date of the transaction	28 May 2019
f)	Place of the transaction	Outside of a trading venue